Background {#sec1}
==========

Colorectal polyps are abnormal growths and protrusions on the colorectal surface \[[@B1],[@B2]\]. The many types of colorectal polyps are classified based on their pathological properties like hyperplastic polyps and adenomatous polyps \[[@B3],[@B4]\]. Hyperplastic polyps have less malignant potential than adenomatous polyps \[[@B4]\]. Although colorectal polyps are considered benign lesions, the malignant transformation of certain polyps, like sessile serrated colorectal polyps, is implicated in the carcinogenic process of the colon and rectum \[[@B5]\]. Endoscopic and laparoscopic surgery can be used to remove colorectal polyps \[[@B2],[@B6],[@B7]\]. Environmental factors, such as cigarette smoking or alcohol consumption, and genetic background may contribute to the initiation or development of colorectal polyps \[[@B8],[@B9]\].

Folate, a water-soluble vitamin, is essential to various biochemical processes of cells, such as cell cycles or nucleic acid synthesis \[[@B10]\]. Homocysteine is linked to one-carbon transfer reaction, the adequate level of SAM and normal DNA methylation reactions \[[@B11]\]. Vitamin B~12~, also termed as cobalamin, has been found to be involved in homocysteine metabolic reactions, DNA synthesis, mitochondrial metabolism, and semen quality \[[@B12],[@B13]\]. Folate, homocysteine, and vitamin B~12~ take part in the transmethylation process, which allows the transfer of methyl groups to specific substrates \[[@B14]\]. Folate deficiency and abnormal folate metabolic pathways are involved in the incidence of DNA hypomethylation or uracil misincorporation, and pathogenesis of several clinical diseases, such as reproductive abnormalities or colorectal cancer (CRC) \[[@B10],[@B15],[@B16]\]. In addition, low folate and low vitamin B~12~ status is correlated with an elevated homocysteine concentration, namely hyperhomocysteinemia, which is associated with several clinical diseases, mostly cardiovascular disorders \[[@B14],[@B17]\].

There is no consensus regarding the correlation between the level of three methyl group donors (folate, homocysteine, and vitamin B~12~) and the risk of colorectal polyps \[[@B15],[@B18]\]. Here, we first conducted a meta-analysis to examine this association using currently available data. The biochemical variables of red blood cell (RBC) folate, serum folate, homocysteine, and vitamin B~12~ were analyzed in cases of colorectal polyps and controls without polyps.

Materials and methods {#sec2}
=====================

Publication searching {#sec2-1}
---------------------

We gathered relevant publications by extensive search of three online databases, including PubMed, WOS (Web of Science), and Embase (Excerpta Medica Database) through August 2017. Here, we list the term of PubMed database searching: ((((((((((((polyps \[MeSH terms\]) OR polyp) OR polyposis) OR colorectal polyps) OR colorectal polyp) OR colorectal polyposis) OR adenomatous polyposis) OR hyperplastic polyps) OR intestinal polyps) OR colonic polyps) OR polyposis coli) AND (((((((((folate) OR serum folate) OR RBC folate) OR red blood cell folate) OR folate status) OR folate metabolism)) OR (((((((homocysteine \[MeSH terms\]) OR 2-amino-4-mercaptobutyric acid) OR 2 amino 4 mercaptobutyric acid) OR homocysteine, L-isomer) OR homocysteine, L Isomer) OR L-Isomer homocysteine) OR plasma homocysteine)) OR ((((((((((vitamin B 12\[MeSH terms\]) OR B 12, vitamin) OR vitamin B12) OR B12, vitamin) OR cyanocobalamin) OR cobalamins) OR cobalamin) OR Eritron) OR VB12) OR serum vitamin B12)).

Study screening {#sec2-2}
---------------

We then independently reviewed and screened the eligible case--control studies using our selection criteria, which were duplicate data; reviews; cases or trials; cell or animal data; meeting abstract or poster; meta-analysis; study of polyps other than colorectal, no mention of folate, homocysteine, or vitamin B~12~ levels; data of intake of folate or vitamin B~12~; lack of control data or S.D. The process of database searching and study selection was performed in accordance with the recommendations regarding preferred reporting items for systematic reviews and meta-analyses (PRISMA) \[[@B30]\].

Data extraction {#sec2-3}
---------------

Next, we performed the data extraction based on the included original case--control studies. A specifically designed table was used to show the detailed characteristics of all studies, including first author name, year of publication, group, number of case--control studies, mean value, S.D. value, race, country, disease type, control source. Missing information is designated 'NA' (not available).

Quantitative synthesis {#sec2-4}
----------------------

Standard mean difference (SMD) was used as the evaluation criterion of the continuous data with varied measurement units, as in similar meta-analyses \[[@B31]\]. Base on Cohen statistics, *P*-value of association test, pooled SMD, and 95% confidence interval (CI) were synthesized in the overall and subgroup meta-analysis by such factors as race, country, and control source. A two-tailed *P*\<0.05 was considered indicative of statistically significant difference. Additionally, based on Q-statistic and *I^2^* test, the evaluation of interstudy heterogeneity was carried out. *P*-values of Q-statistic \< 0.05 or *I^2^* values \> 50% were considered indicative of high heterogeneity. We here used an inverse variance (IV)-weighted, random-effects model.

Publication bias {#sec2-5}
----------------

Both Begg's test and Egger's test were performed to quantitatively judge the possible publication bias. *P*-value of Begg's test and Egger's test \< 0.05, and asymmetric funnel plot indicate significant publication bias.

Sensitivity analysis {#sec2-6}
--------------------

We performed a sensitivity analysis to evaluate the sources of heterogeneity and stability of the data. We removed each case--control study from the analysis one by one and analyzed differences in pooled data. All these tests were performed using STATA software (Stata Corp, College Station, TX, U.S.A.).

Results {#sec3}
=======

Included studies {#sec3-1}
----------------

We gathered a total of 852 relevant publications from a search of three databases, specifically 201 publications in PubMed, 228 in WOS, and 423 in Embase. Of 852 publications, the following records were excluded: duplicate publications (*n*=258), reviews (*n*=256), cases or trials (*n*=40), cell or animal data (*n*=39), meeting abstract or poster (*n*=64), meta-analysis (*n*=8), polyps that were not colorectal (*n*=76), or the absence of folate, homocysteine, and vitamin B~12~ levels (*n*=56). We then obtained a total of 55 publications with full text for eligibility and removed 31 publications containing the data of intake of folate or vitamin B~12~, and 11 publications that lacked control data or S.D. data. Finally, a total of 13 case--control studies \[[@B15],[@B18]\] were enrolled for our quantitative synthesis. We show the inclusion process in [Figure 1](#F1){ref-type="fig"} and provide detailed characteristics in [Table 1](#T1){ref-type="table"}. We did not obtain the detailed information of hospital or population-based control (PB) source in several studies, which were recorded as 'NA' ([Table 1](#T1){ref-type="table"}).

![PRISMA-based flowchart of database searching and study selection](bsr-38-bsr20171699-g1){#F1}

###### Characteristics of studies included in this meta-analysis

  First author                      Year   Group           Case   Race   Country   Control     Disease type   Source                                                              
  --------------------------------- ------ --------------- ------ ------ --------- ----------- -------------- -------- ------- ----- -------------------------------------------- ----
  **Ashktorab et al.** \[[@B29]\]   2007   Serum folate    11.8   4.2    23        Caucasian   U.S.A.         12.7     4       35    Colorectal polyps                            HB
                                           RBC folate      438    140    23        Caucasian   U.S.A.         435      117     35    Colorectal polyps                            
                                           Homocysteine    11.2   3.4    23        Caucasian   U.S.A.         10.9     5       35    Colorectal polyps                            
                                           Vitamin B~12~   561    312    23        Caucasian   U.S.A.         531      265     35    colorectal polyps                            
  **Beckett et al.** \[[@B28]\]     2015   RBC folate      1.29   0.12   26        Caucasian   Australia      0.93     0.04    118   Female - adenomatous polyps                  NA
                                           RBC folate      0.89   0.07   30        Caucasian   Australia      1.1      0.05    79    Male - adenomatous polyps                    
                                           Vitamin B~12~   0.29   0.02   26        Caucasian   Australia      0.28     0.01    118   Female - adenomatous polyps                  
                                           Vitamin B~12~   0.27   0.02   30        Caucasian   Australia      0.27     13.1    79    Male - adenomatous polyps                    
                                           Homocysteine    12.4   0.79   26        Caucasian   Australia      12       0.4     118   Female - adenomatous polyps                  
                                           Homocysteine    13.8   1.21   30        Caucasian   Australia      13.6     0.52    79    Male - adenomatous polyps                    
  **Chen et al.** \[[@B27]\]        2014   Homocysteine    12.8   6.6    51        Asian       China          11.2     4.3     99    Colorectal polyps -metabolic syndrome (--)   PB
                                           Homocysteine    14     6.1    59        Asian       China          11.9     2.9     36    Colorectal polyps-metabolic syndrome (+)     
  **Chen et al.**\[[@B26]\]         2013   Homocysteine    14.2   5.5    29        Asian       China          9.8      2.1     96    Adenomatous polyps                           PB
                                           Homocysteine    14.5   7.4    19        Asian       China          9.8      2.1     96    Hyperplastic polyps                          
                                           Serum folate    23.9   17.2   29        Asian       China          19.7     11      96    Adenomatous polyps                           
                                           Serum folate    18.6   9      19        Asian       China          19.7     11      96    Hyperplastic polyps                          
                                           Vitamin B~12~   334    189    29        Asian       China          373      205.4   96    Adenomatous polyps                           
                                           Vitamin B~12~   355    162    19        Asian       China          373      205.4   96    Hyperplastic polyps                          
  **Chiang et al.** \[[@B25]\]      2015   Homocysteine    13.3   4.94   70        Asian       China          11.6     4.97    182   Adenomatous polyps                           PB
                                           Serum folate    13.3   9.14   70        Asian       China          15.3     8.31    182   Adenomatous polyps                           
  **Choi et al.** \[[@B24]\]        2015   RBC folate      974    511    37        Caucasian   Australia      1045     576.1   162   Adenomatous polyps                           NA
                                           Homocysteine    9.9    2.9    37        Caucasian   Australia      10       2.6     162   Adenomatous polyps                           
  **Levine et al.** \[[@B23]\]      2000   RBC folate      261    146    518       Caucasian   U.S.A.         270      153.2   554   Adenomatous polyps                           PB
  **Lim et al.** \[[@B22]\]         2012   Homocysteine    13.3   3.9    422       Asian       Korea          13.2     5.88    617   Adenomatous polyps                           PB
  **Lucock et al.** \[[@B21]\]      2011   RBC folate      990    87     38        Caucasian   Australia      914      33      164   Adenomatous polyps                           NA
                                           Serum folate    20.2   1.9    38        Caucasian   Australia      19.5     0.8     164   Adenomatous polyps                           
  **Lucock et al.** \[[@B20]\]      2015   Homocysteine    13.2   0.73   57        Caucasian   Australia      12.7     0.322   192   Adenomatous polyps                           PB
  **McGlynn et al.** \[[@B15]\]     2013   RBC folate      474    234    40        Caucasian   Ireland        524      285     53    Adenomatous polyps                           HB
                                           RBC folate      561    290    16        Caucasian   Ireland        524      285     53    Hyperplastic polyps                          
                                           Homocysteine    11.9   5.5    40        Caucasian   Ireland        9.4      2.4     53    Adenomatous polyps                           
                                           Homocysteine    10.2   2.4    16        Caucasian   Ireland        9.4      2.4     53    Hyperplastic polyps                          
                                           Vitamin B~12~   356    162    40        Caucasian   Ireland        383      168     53    Adenomatous polyps                           
                                           Vitamin B~12~   446    184    16        Caucasian   Ireland        383      168     53    Hyperplastic polyps                          
  **Paspatis et al.** \[[@B19]\]    1995   Serum folate    4.57   2.8    62        Caucasian   Greece         5.09     2.7     50    Adenomatous polyps                           HB
                                           RBC folate      536    273    62        Caucasian   Greece         744      297.1   50    Adenomatous polyps                           
  **Powers et al.** \[[@B18]\]      2007   Vitamin B~12~   346    214    91        Caucasian   Ireland        311      190.1   85    Colorectal polyps                            PB

Abbreviations: HB, hospital-based; NA, not available; PB, population-based.

Meta-analysis of folate {#sec3-2}
-----------------------

To evaluate the association between level of serum/RBC folate and risk of colorectal polyps, six case--control studies with 241 cases and 623 controls were enrolled for meta-analysis of serum folate, while 9 case--control studies with 790 cases and 1268 controls were for RBC folate ([Table 2](#T2){ref-type="table"}). Compared with controls, no increased colorectal polyp risk in cases was detected in the overall meta-analysis ([Table 2](#T2){ref-type="table"}, *P*\>0.05). We also conducted subgroup analyses by country, race, and control source. Similar negative results were obtained ([Table 2](#T2){ref-type="table"}, all *P*\>0.05). It should be noted that we only show the results of subgroup analysis with more than or equal to three case-control studies in the present study. Forest plots of each subgroup analysis by race are given in [Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. These findings suggest that the level of serum or RBC folate seems not to be associated with colorectal polyp risk.

![Subgroup analysis of association between serum folate level and risk of colorectal polyps stratified by race](bsr-38-bsr20171699-g2){#F2}

![Subgroup analysis of association between RBC folate level and risk of colorectal polyps stratified by race](bsr-38-bsr20171699-g3){#F3}

###### Meta-analysis of serum folate and RBC folate

  Group              Subgroup (factor)[\*](#T2TFN1){ref-type="table-fn"}   Sample size   Test of association                                
  ------------------ ----------------------------------------------------- ------------- --------------------- --------------------- ------ -------
  **Serum folate**   Overall                                               6             241/623               0.04 (−0.27, 0.36)    0.28   0.783
                     China (country)                                       3             118/374               −0.02 (−0.37, 0.33)   0.11   0.909
                     Caucasian (race)                                      3             579/753               0.09 (−0.50, 0.68)    0.31   0.760
                     Asian (race)                                          3             118/374               −0.02(−0.37, 0.33)    0.11   0.909
                     PB (control source)                                   3             118/374               −0.02 (−0.37, 0.41)   0.11   0.909
  **RBC folate**     Overall                                               9             790/1268              0.28 (−0.60, 1.15)    0.62   0.536
                     Australia (country)                                   4             131/523               0.87 (−1.89, 3.63)    0.62   0.537
                     HB (control source)                                   4             141/191               −0.22 (−0.62, 0.17)   1.10   0.272
                     Caucasian (race)                                      9             790/1268              0.28 (−0.60, 1.15)    0.62   0.536

Abbreviations: HB, hospital-based; PB, population-based.

Only the results of subgroup meta-analysis with more than or equal to three case--control studies were provided.

Meta-analysis of homocysteine, vitamin B~12~ {#sec3-3}
--------------------------------------------

Thirteen case--control studies involving 879 cases and 1818 controls were enrolled in this meta-analysis regarding the relationship between the level of homocysteine and colorectal polyp risk. Data from the overall meta-analysis ([Table 3](#T3){ref-type="table"}) indicated homocysteine level in colorectal polyp cases was higher than in controls free of colorectal polyps (*P*\<0.001, SMD = 0.52, 95% CIs = 0.25--0.78). Data from the subgroup analysis of hospital-based control (HB), PB, China, Caucasian, and Asian showed similar positive results ([Table 3](#T3){ref-type="table"}, all *P*\<0.05, SMD \> 0). However, no significant difference between cases and controls was observed in the overall or subgroup meta-analyses of vitamin B~12~ ([Table 3](#T3){ref-type="table"}, all *P*\>0.05). [Figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"} show the forest plots. An elevated level of homocysteine was statistically significantly associated with the risk of colorectal polyps.

![Subgroup analysis of association between homocysteine level and risk of colorectal polyps stratified by race](bsr-38-bsr20171699-g4){#F4}

![Subgroup analysis of association between vitamin B~12~ level and risk of colorectal polyps stratified by race](bsr-38-bsr20171699-g5){#F5}

###### Meta-analysis of homocysteine, vitamin B~12~

  Comparison          Subgroup (factor)[\*](#T3TFN1){ref-type="table-fn"}   Sample size   Test of association                               
  ------------------- ----------------------------------------------------- ------------- --------------------- -------------------- ------ ---------
  **Homocysteine**    Overall                                               13            879/1818              0.52 (0.25, 0.78)    3.84   \<0.001
                      HB (control source)                                   3             79/141                0.37 (0.05, 0.70)    2.23   0.026
                      PB (control source)                                   7             707/1318              0.67 (0.26, 1.08)    3.17   0.002
                      Australia (country)                                   4             150/551               0.52 (−0.03, 1.07)   1.86   0.064
                      China (country)                                       5             228/509               0.72 (0.28, 1.16)    3.21   0.001
                      Caucasian (race)                                      7             229/692               0.45 (0.10, 0.80)    2.54   0.011
                      Asian (race)                                          6             650/1126              0.59 (0.18, 1.00)    2.83   0.005
  **Vitamin B~12~**   Overall                                               8             274/615               0.12 (−0.11, 0.35)   1.03   0.305
                      HB (control source)                                   3             79/141                0.05 (−0.25, 0.36)   0.35   0.729
                      PB (control source)                                   3             139/277               0.01 (−0.22, 0.24)   0.11   0.912
                      Ireland (country)                                     3             147/191               0.10 (−0.16, 0.37)   0.76   0.449
                      Caucasian (race)                                      6             226/423               0.21 (−0.06, 0.48)   1.49   0.135

Abbreviations: HB, hospital-based; PB, population-based.

Only the results of subgroup meta-analysis with more than or equal to three case--control studies were provided.

Heterogeneity, bias, and sensitivity analysis {#sec3-4}
---------------------------------------------

Obvious heterogeneity was detected in all the comparisons given above ([Table 4](#T4){ref-type="table"}, all *I^2^* \> 50.0%, *P*-value of heterogeneity \<0.05), and IV-weighted random effect models were thus used in Cohen statistics. For publication bias, as shown in [Table 4](#T4){ref-type="table"}, apart from Egger's test of homocysteine (*P*=0.024), *P*-value of Begg's test and Egger's test was larger than 0.05 in others, indicating the absence of large publication bias. Begg's funnel plot for the association of homocysteine level and colorectal polyp risks is shown in [Figure 6](#F6){ref-type="fig"}A (homocysteine), and Supplementary Figures S1A (serum folate), S2A (RBC folate), S3A (vitamin B~12~). In addition, similar pooled ORs were observed in our sensitivity analysis, as shown in [Figure 6](#F6){ref-type="fig"}B (homocysteine), Supplementary Figures S1B (serum folate), S2B (RBC folate), and S3B (vitamin B~12~).

![Begg's funnel plot and sensitivity analysis for homocysteine level and risk of colorectal polyps\
(**A**) Begg's funnel plot; (**B**) sensitivity analysis.](bsr-38-bsr20171699-g6){#F6}

###### Assessment of heterogeneity and publication bias

  Group               *I^2^*   *P*-value   Model    Begg's test   Egger's test          
  ------------------- -------- ----------- -------- ------------- -------------- ------ -------
  **Serum folate**    73.8%    0.002       Random   0.00          1.000          0.23   0.831
  **RBC folate**      98.1%    \<0.001     Random   0.94          0.348          0.39   0.707
  **Homocysteine**    87.0%    \<0.001     Random   0.79          0.428          2.61   0.024
  **Vitamin B~12~**   55.0%    0.030       Random   0.87          0.386          0.10   0.921

Discussion {#sec4}
==========

Because of the important role of methyl group donors, various studies investigated the role of folate, homocysteine, vitamin B~12~ in several clinical diseases. However, no final conclusion was drawn. In 2016, Cao et al. \[[@B34]\] conducted a meta-analysis of 20 eligible studies and found that lower folate level may be related to the risk of schizophrenia. In 2017, the meta-analysis data reported by Wang et al. \[[@B35]\] showed the correlation between reduced serum levels of folate and vitamin B~12~ and the risk of type 2 diabetes mellitus in a Chinese population. The low level of folate was also reported to be linked to the risk of inflammatory bowel disease but that of vitamin B~12~ was not \[[@B36]\]. Ramanujam et al. \[[@B37]\] performed another meta-analysis and found that low folate levels were not statistically significantly associated with the risk of depression.

With regard to CRC, several meta-analyses without consistent conclusions \[[@B38]\] explored the association between folic acid supplementation or folate intake and the risk of CRC. A meta-analysis by Kennedy et al. \[[@B38]\] in 2011 showed that higher folate intake level was important for the reduced risk of CRC. However, the negative correlation between folate supplementation and the risk of CRC was also reported in another meta-analysis in 2015 \[[@B40]\]. Colorectal polyps were considered precursors of CRC. Nevertheless, we failed to observe the relevant meta-analysis for the effect of folate, homocysteine, vitamin B~12~ in the risk of colorectal polyps. We also observed the different reports in distinct populations. For instance, the high level of folate was reported to be associated with the increased risk of CRC patients with adenomatous polyps, but not in CRC patients without adenomatous polyps in a Chinese population \[[@B25]\]. The evaluated plasma homocysteine level was associated with an increased susceptibility to colorectal polyps in Chinese population \[[@B26]\]. However, no relationship was found between the level of serum folate, RBC folate, vitamin B~12~, or homocysteine and risk of colon polyps in African Americans \[[@B29]\]. We were, therefore, very interested in enrolling all the published articles to assess this relationship.

According to our strict searching and screening requirements, a total of 13 eligible case--control studies containing data covering sample size, mean value, and S.D. were enrolled. Our findings showed that the level of homocysteine in colorectal patients with polyps was significantly higher than that in controls without polyps. In contrast, the level of serum folate, RBC folate, and vitamin B~12~ did not differ between polyp patients and controls.

Several limitations should be fully considered. (i) As in other meta-analyses, there exists the problem of limited case--control studies for quantitative synthesis. Only one study provided data covering the association between serum vitamin B~12~ level and colorectal polyps in an Asian population \[[@B26]\], which caused the subgroup analysis of Asians for vitamin B~12~ to fail. Here, we only provided the data of subgroup meta-analysis using such factors as country, race, and control source when there were three or more case--control studies included. Additionally, although no statistical effect was observed the level of serum folate, RBC folate, and vitamin B~12~, we still cannot disregard their potential influence in the progression of colorectal polyps yet because of the limited sample size. (ii) A higher plasma homocysteine concentration was reported to be associated with the risk of advanced adenoma in female Korean participants, but not in the overall population \[[@B22]\]. The influence of folate supplementation on changes in the number of recurrent polyps was also reported \[[@B41]\]. For this reason, we performed further detailed subgroup analyses by specific disease type, gender, should be performed, whenever we were able to acquire more data. More biochemical variables, such as plasma riboflavin (nmol/l) and plasma flavinsk (nmol/l), should be investigated as well. (iii) Our meta-analysis showed considerable heterogeneity. We note that the control groups of some of the studies included here were hospital-based and, in some cases, relevant information was unavailable. We did not observe any obvious decrease in heterogeneity in our stratified meta-analyses (data not shown). Insufficient data may prevent successful identification of the cause of heterogeneity. (iv) Slight publication bias was observed in the Egger's test of homocysteine, which may reduce the statistical power with respect to the positive correlation between homocysteine level and colorectal polyp susceptibility to some extent.

Data regarding several studies support the association between the high homocysteine concentrations in the risk of developing CRC \[[@B42],[@B43]\]. However, the specific mechanism underlying the role of an increased homocysteine level in susceptibility to colorectal polyps remains elusive. Folate metabolism is dependent on 5,10-methylenetetrahydrofolate (MTHFR) enzyme, which catalyzes the conversion of MTHFR into 5-methyltetrahydrofolate (5-methyl THF) \[[@B14]\]. Vitamin B~12~ is also essential to the conversion of homocysteine into methionine \[[@B14]\]. Homozygous and heterozygous mutations of the *MTHFR* gene for C677T polymorphism have been reported to render enzyme activity lower than in the wild-type genotype \[[@B14],[@B17]\]. We should also consider more factors, such as genomic instability, DNA synthesis, CpG sequences methylation, and other epigenetic changes.

Conclusion {#sec5}
==========

Generally speaking, quantitative synthesis data provide evidence regarding the role of an elevated homocysteine level in the developing colorectal polyp risk. Larger sample sizes were still required to investigate whether serum folate, RBC folate, and vitamin B~12~ levels function in the susceptibility to colorectal polyps.
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